Efficacy

Using Human-on-a-Chip technology to reduce animal testing in drug discovery
by

Senior Editor with Pharma Manufacturing interviews Hesperos executives Michael Shuler and Nathan Post on the rise of Human-on-a-Chip (HoaC) systems and how they are replacing the need for animal testing in drug discovery.

human-on-a-chip
by

Presentation Highlights

This is a company overview presentation given by Dr. James Hickman at this years Florida Simulation Summit 2020 in October.  Learn more about the technology and exciting path ahead. Key highlights from the presentation include:

  • A brief history of Hesperos
  • How the Human-on-a-Chip technology works and the current state of the technology
  • Key applications and path forward

Human-on-a-Chip®

Functional in vitro models that accurately predict how new drug candidates will impact the human body – something that has previously required animal testing or human clinical trials to determine.

What’s on each Chip?

Systemic toxicology models with interlinked organs, including: heart, liver, lung, brain, skin, muscle, GI tract, kidney, pancreas, endocrine, bone marrow and the neuromuscular junction in a serum free, recirculating medium utilizing a pumpless platform.

hesperos
by

HUMAN-ON-A-CHIP MODEL ENABLES SIMULTANEOUS TESTING OF CANCER DRUG EFFICACY AND OFF-TARGET TOXICITY TO ENABLE DETERMINATION OF THERAPEUTIC INDEX In vitro multi-organ system by Hesperos, Inc. realistically replicates the responses of cancer treatments and has potential to … Read More